Prosecution Insights
Last updated: April 19, 2026

Ablevia Biotech GmbH

2 pending office actions

Portfolio Summary

2
Total Pending OAs
1
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18246122 COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTI-PEG ANTIBODIES IN A PATIENT LIPPERT, JOHN WILLIAM 1615 Final Rejection Mar 21, 2023
18245959 COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTIBODIES IN A PATIENT DAHLE, CHUN WU 1641 Non-Final OA Mar 20, 2023

Managing Ablevia Biotech GmbH's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month